Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
== Organizational structure == The Commission consists of the chairman and other members appointed by the President of the Republic of India. Usually, the Commission consists of 9 to 11 members, including the chairman. Every member holds office for a term of six years or until he attains the age of sixty-five years, whichever is earlier. The terms and conditions of service of the chairman and members of the commission are governed by the Union Public Service Commission (Members) Regulations, 1969. The chairman and any other member of the commission can submit their resignation at any time to the President of India. They may be removed from their office by the President of India on the ground of misbehavior (only if an inquiry of such misbehavior is made and upheld by the Supreme Court) or if he is adjudged insolvent, or engages during the term of office in any paid employment outside the duties of their office, or in the opinion of the president unfit to continue in office because of the infirmity of mind or body.
=== Synthetic alizarin 1868 – 1873 === The development of synthetic alizarin opened up a huge market that was formerly served by natural dye makers. Alizarin was the first dye whose structure chemist determined, and they quickly set it as a target of synthesis, succeeding by 1868. Other chemical components of natural madder were identified and applied by the mid-19th century, including purpurin, which produced a delicate lilac colour, and green alizarin, which was patented in Britain and famously displayed at the 1867 Paris International Exhibition. Similar to aniline dyes, the precursors for Synthetic Alizarin were easily obtainable from coal tar. Germany dominated the synthetic alizarin market, however foreign competition was not non-extant, for example the British Alizarine Company Ltd.
Napoleon's Wars: An International History, 1803–1815. Penguin Books. ISBN 978-0-14-311628-8. Ferguson, Niall (2008). The Ascent of Money: A Financial History of the World: 10th Anniversary Edition. Penguin. ISBN 978-1-4406-5402-2. Fremont-Barnes, Gregory (2014). The Napoleonic Wars (3): The Peninsular War 1807–1814. Bloomsbury Publishing. ISBN 978-1-4728-0975-9. Gates, David (1986). The Spanish Ulcer: A History of the Peninsular War. Allen & Unwin. ISBN 978-0-04-940079-5. Glover, Michael (1963). Wellington's Peninsular Victories: Busaco, Salamanca, Vitoria, Nivelle. Macmillan. Götz, Norbert (6 June 2014). "The Good Plumpuddings' Belief: British Voluntary Aid to Sweden During the Napoleonic Wars". The International History Review. 37 (3): 519–539. doi:10.1080/07075332.2014.918559. ISSN 0707-5332. Grab, Alexander (2003). Napoleon and the Transformation of Europe. Macmillan International Higher Education. ISBN 978-1-4039-3757-5. Grainger, John D. (2004). The Amiens Truce: Britain and Bonaparte, 1801–1803. Boydell Press. ISBN 978-1-84383-041-2. Gray, Colin S. (2007). War, Peace and International Relations: An Introduction to Strategic History. Routledge. ISBN 978-1-134-16951-1. Halévy, Elie (1924). A History of the English People ...: England in 1815. Harcourt, Brace. Haythornthwaite, Philip; et al. (Illustrations and graphics by Peter Dennis) (20 September 2012). Cowper, Marcus (ed.). Borodino 1812: Napoleon's great gamble. Campaign. Vol. 246. London, England, United Kingdom of Great Britain: Bloomsbury Publishing. ISBN 9781849086974.
If some of the fish they had previously eaten is available this can also be tested to confirm the diagnosis. Preventive efforts include not eating reef fish, not eating high-risk fish such as barracuda, and not eating fish liver, roe, or fish heads. The toxins have no taste or smell, and cannot be destroyed by conventional cooking. There is no specific treatment for ciguatera fish poisoning once it occurs. Mannitol may be considered, but the evidence supporting its use is not very strong. Gabapentin or amitriptyline may be used to treat some of the symptoms. In 2017, the United States Centers for Disease Control (CDC) estimated that around 50,000 cases occur globally each year. Other estimates suggest up to 500,000 cases per year. The risk of death from poisoning is less than 1 in 1,000 according to the CDC. It is the most frequent seafood poisoning, and up to 5% of patients may develop chronic symptoms, which are treatable using the protocols for Chronic Inflammatory Response Syndrome (CIRS) It occurs most commonly in the Pacific Ocean, Indian Ocean, and the Caribbean Sea between the latitudes of 35°N and 35°S. The risk of the condition appears to be increasing due to coral reef deterioration and increasing trade in seafood. Descriptions of the condition date back to at least 1511. The current name, introduced in 1787, is of Cuban Spanish origin and originally referred to the gastropod Cittarium pica.
== External links == "Burkholderia pseudomallei genomes and related information". PATRIC. NIAID. Archived from the original on 2011-08-24. Retrieved 2010-06-24. "Getting a Grip on the Great Mimicker: Secrets of a Stealth Organism". Wellcome Trust. Archived from the original on 2009-09-27. Retrieved 2006-03-27. Pathema Burkholderia resource "Burkholderia pseudomallei". NCBI Taxonomy Browser. 28450.
Sources: en.wikipedia.org
1994 Malaysian football scandal 1999 Chinese football match-fixing scandal 2001 Chinese football match-fixing scandal 2003–2009 Chinese football match-fixing scandals Apito Dourado (2004) – a match fixing scandal in Portuguese football involving FC Porto, Boavista, and União de Leiria. Bundesliga scandal (2005) – a match fixing scandal in German football centering on disgraced referee Robert Hoyzer. Caso Genoa (2005) Brazilian football match-fixing scandal (2005) – a match fixing scandal involving referees in Brazil. 2006 Calciopoli scandal – a match fixing scandal in Italian football involving several major teams, including three of the country's four qualifiers to the 2006–07 UEFA Champions League. In the Commonwealth of Independent States Cup 2006, the Armenian champion Pyunik refused to play with an Azerbaijani team, PFC Neftchi. The team Pyunik defeated the Ukrainian team Shakhtar Donetsk 3–1 in the quarter-final, when it already knew that in case of victory they would have to play against Neftchi. After the match, they told the referee they would not play against an Azerbaijani team and later that evening left Moscow on an airplane. The Russian Football Union gave Shakhtar Donetsk a technical victory 3–0 so they could play in the half-final instead of Pyunik, but Shakhtar Donetsk declined the offer stating that "[W]e would really want to play in the half-final, but we don't want to get there by any other way then sport".
Tacrolimus is a macrolide calcineurin inhibitor. In T cells, activation of the T cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. Calcineurin then dephosphorylates the transcription factor nuclear factor of activated T cells (NF-AT), which moves to the nucleus of the T cell and increases the activity of genes coding for IL-2 and related cytokines. Tacrolimus prevents the dephosphorylation of NF-AT. In detail, tacrolimus reduces peptidylprolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein), creating a new complex. This FKBP12–FK506 complex interacts with and inhibits calcineurin, thus inhibiting both T lymphocyte signal transduction and IL-2 transcription. Although this activity is similar to that of cyclosporin, the incidence of acute rejection is reduced by tacrolimus use over cyclosporin use. Although short-term immunosuppression concerning patient and graft survival is found to be similar between the two drugs, tacrolimus results in a more favorable lipid profile, and this may have important long-term implications given the prognostic influence of rejection on graft survival.
== Further reading == Arms, Thomas S. Encyclopedia of the Cold War (1994). Brune, Lester H. Chronology of the Cold War, 1917–1992 (Routledge, 2006) 720 pp of brief facts Hanes, Sharon M. and Richard C. Hanes. Cold War Almanac (2 vol 2003), 1460pp of brief facts Parrish, Thomas. The Cold War Encyclopedia (1996) Trahair, Richard C.S. and Robert Miller. Encyclopedia of Cold War Espionage, Spies, and Secret Operations (2012). excerpt Tucker, Spencer C. and Priscilla Mary Roberts, eds. The Encyclopedia of the Cold War: A Political, Social, and Military History (5 Vol., 2007). excerpt van Dijk, Ruud, ed. Encyclopedia of the Cold War (2 vol. 2017) excerpt
All three polymorphs crystallize simultaneously from aqueous solutions under ambient conditions. In additive-free aqueous solutions, calcite forms easily as the major product, while aragonite appears only as a minor product. At high saturation, vaterite is typically the first phase precipitated, which is followed by a transformation of the vaterite to calcite. This behavior seems to follow Ostwald's rule, in which the least stable polymorph crystallizes first, followed by the crystallization of different polymorphs via a sequence of increasingly stable phases. However, aragonite, whose stability lies between those of vaterite and calcite, seems to be the exception to this rule, as aragonite does not form as a precursor to calcite under ambient conditions.
== Recent research == The Development of ELISA testing for specific diagnosis of PNP was released in 2009. The research focuses on the specific determination of autoantibodies involved in the mechanism of PNP. Specifically, antibodies against envoplakin and periplakin were being investigated. Further use of ELISA testing on these antibodies confirmed the presence of anti-envoplakin and anti-periplakin autoantibodies in patients with PNP. Further research in 2013 outlined the various types of assays that could be used to determine which antibodies were involved in PNP. Demonstration of certain antibodies in the serum was named as the basis for diagnosis of PNP. This piece labeled PNP as a "multiorgan disease characterized by antibodies against plakins, desmogleins and the α2-macroglobulin-like-1 (A2ML1) protein, in association with an underlying neoplasm". A study concluded in 2009, summarized in 2010, surrounded the surgical removal of the associated tumor as a means to treat PNP. While 7/22 of the subjects perished due to resulting infection from the body's inability to heal itself after surgery, the other 15 cases survived. This study outlined the importance of early detection and prompt treatment as of utmost important in the treatment of PNP. In 2011, a case study of a woman with ulcers on the back of her leg reported as being diagnosed with PNP. The underlying tumors are almost exclusively of B-cell lineage. However, T-cells and CD56+ Natural Killer cells have also been postulated to be associated effectors of paraneoplastic pemphigus.
Sources: en.wikipedia.org
Nicotinamide-nucleotide adenylyltransferase (NMNAT) (EC 2.7.7.1) is an enzyme that catalyzes the reversible chemical reaction that produces nicotinamide adenine dinucleotide from adenosine triphosphate and nicotinamide mononucleotide.
=== Post-translational conjugation === This technique fuses protein domains following ribosomal translation of the proteins of interest, in contrast to genetic fusion prior to translation used in other recombinant technologies.
=== GDGT-0 === GDGT-0 has zero cyclopentane moieties and is the most ubiquitous isoGDGT synthesized by archaea. Halophilic archaea are the only group of archaea not known to produce GDGT-0. Carbon isotope analyses and association with sites of anaerobic methane oxidation suggest that GDGT-0 is produced via methanotrophs. In microbiology literature not dealing with the geological record, GDGT-0 is sometimes referred to as caldarchaeol.
== Horizontal gene transfer == Horizontal gene transfer (HGT) is the movement of genetic information between different organisms of the same species mainly being bacteria. This is not the movement of genetic information between a parent and their offspring but by other factors. In contrast to how animals reproduce and evolve from sexual reproduction, bacteria evolve by sharing DNA with other bacteria or their environment. There are three common mechanisms of transferring genetic material by HGT:
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.